ETON

#2120
Eton Pharmaceuticals, Inc. - Common Stock
59.7 8 USD
-0.05%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
59.78
59.78
Intervallo Annuale
14.27
66.37
Variazione giornaliera
-4.61%
Variazione Mensile
+21.78%
Variazione di 6 mesi
+254.99%
Variazione Annuale
+250.62%
Chiusura Precedente
62.6 7
Open
59.7 8
Minimo
59.7 8
Massimo
59.7 8
Volume
63
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Eton Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Eton Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Eton Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Eton Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Eton Pharmaceuticals, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K

Eton Pharmaceuticals, Inc. current report, Q2 FY2020

Full document

Eton Pharmaceuticals, Inc. - 8-K Summary

Business Context and Reporting Period

This Form 8-K reports on the 2020 Annual Meeting of Stockholders held on June 9, 2020, in Deer Park, Illinois. Eton Pharmaceuticals, Inc. is an emerging growth company incorporated in Delaware with its common stock trading on the NASDAQ Global Select Market under the symbol ETON.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.

Material Changes and Voting Results

Stockholders voted on two proposals at the Annual Meeting:

  • Proposal 1: Election of Directors
    • Mark L. Baum: Elected with 11,227,048 votes For, 114,060 Against, and 3,196 Abstentions. There were 5,758,947 Broker Non-Votes.
    • Charles J. Casamento: Elected with 9,695,663 votes For, 1,645,445 Against, and 3,196 Abstentions. There were 5,758,947 Broker Non-Votes.
  • Proposal 2: Ratification of Independent Auditor
    • KMJ Corbin & Company LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2020.
    • Votes: 16,627,487 For, 99,760 Against, and 376,004 Abstentions. There were 0 Broker Non-Votes.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.

Key Facts for Investor Verification

  • Both director nominees, Mark L. Baum and Charles J. Casamento, were successfully elected for three-year terms.
  • Stockholders approved the appointment of KMJ Corbin & Company LLP as the independent auditor.
  • A significant number of broker non-votes (5,758,947) were recorded for the director elections, indicating shares held by brokers that were not voted on these matters.
  • The company has elected to use the extended transition period for complying with new or revised financial accounting standards as an emerging growth company.

Notizie